selank comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Since Xi became general secretary, censorship has stepped up. Xi has overseen the increased coordination and consolidation of censorship authorities, raising their efficiency, and under his leadership censorship practices have tightened. Xi has called on for more positive energy at Chinese media, referring to the need for uplifting messages as opposed to critical or negative ones. In August 2013, he gave what became known as the August 19 speech, emphasizing the guiding role of ideology in propaganda. At the Symposium on News Reporting and Public Opinion in 2016, Xi stated that "party and government-owned media must hold the family name of the party" and that the state media "must embody the party's will, safeguard the party's authority". Xi's administration has overseen more Internet restrictions imposed, and is described as being "stricter across the board" on speech than previous administrations. In 2013, the State Internet Information Office summoned influential bloggers to a seminar to instruct them to avoid writing about politics, the CCP, or making statements contradicting official narratives. Many bloggers stopped writing about controversial topics, and Weibo went into decline, with much of its readership shifting to WeChat users speaking to limited social circles. The SIIO also formulated the Seven Bottom Lines, which serve as the bottom lines that internet users and social media companies in China must adhere to.
=== Indirect size measurement of intact complexes === Sedimentation-velocity analytical ultracentrifugation (measures the translational diffusion constant) Dynamic light scattering (measures the translational diffusion constant) Pulsed-gradient protein nuclear magnetic resonance (measures the translational diffusion constant) Fluorescence polarization (measures the rotational diffusion constant) Dielectric relaxation (measures the rotational diffusion constant) Dual polarisation interferometry (measures the size and the density of the complex) Methods that measure the mass or volume under unfolding conditions (such as MALDI-TOF mass spectrometry and SDS-PAGE) are generally not useful, since non-native conditions usually cause the complex to dissociate into monomers. However, these may sometimes be applicable; for example, the experimenter may apply SDS-PAGE after first treating the intact complex with chemical cross-link reagents.
== Patents == Although details have not surfaced, it appears that the University of Utah forced the 23 March 1989 Fleischmann and Pons announcement to establish priority over the discovery and its patents before the joint publication with Jones. The Massachusetts Institute of Technology (MIT) announced on 12 April 1989 that it had applied for its own patents based on theoretical work of one of its researchers, Peter L. Hagelstein, who had been sending papers to journals from 5 to 12 April. An MIT graduate student applied for a patent but was reportedly rejected by the USPTO in part by the citation of the "negative" MIT Plasma Fusion Center's cold fusion experiment of 1989. On 2 December 1993 the University of Utah licensed all its cold fusion patents to ENECO, a new company created to profit from cold fusion discoveries, and in March 1998 it said that it would no longer defend its patents. The U.S. Patent and Trademark Office (USPTO) now rejects patents claiming cold fusion. Esther Kepplinger, the deputy commissioner of patents in 2004, said that this was done using the same argument as with perpetual motion machines: that they do not work. Patent applications are required to show that the invention is "useful", and this utility is dependent on the invention's ability to function.
Sources: en.wikipedia.org
Wakame Seaweed Archived 2016-04-21 at the Wayback Machine at About.com AlgaeBase link Undaria pinnatifida Archived 2019-09-24 at the Wayback Machine at the FAO Undaria pinnatifida at the Joint Nature Conservation Committee, UK Global Invasive species database Archived 2011-06-11 at the Wayback Machine Undaria Management at the Monterey Bay National Marine Sanctuary
In October 2023, the company announced it would acquire ocedurenone – an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases – from KBP Biosciences for $1.3 billion. After a failed clinical trial the following year, Novo initiated legal action against KBP alleging that the company misrepresented the drug's effectiveness by concealing unfavorable clinical trial data. Seeking up to $830 million in damages, the Singapore International Commercial Court granted Novo's request for a freeze on KBP's assets and those of its founder, Huang Zhenhua. In November 2023, Novo announced investment of €2.1 billion in a French production facility to increase the production capacity and manufacturing of its popular anti-obesity medication. In February 2024, parent company Novo Holdings agreed to acquire Catalent for $16.5 billion. On completion, Novo said it would acquire three manufacturing facilities from its parent for $11 billion to scale up production to meet the massive demand for Wegovy and Ozempic. In March 2024, Novo reached a $604 billion market capitalization and became the 12th most valuable company in the world. The company's stock jumped to a record high after early trial data showed positive results for its new experimental weight loss pill amycretin. The company also announced it would acquire Cardior Pharmaceuticals and its cardiovascular disease portfolio for up to $1.1 billion.
=== Procedure === During the insertion procedure, the provider will first insert a speculum into the vagina to get a good view of the cervix (the opening to the uterus). The provider will then cleanse the cervix. Next, the provider will hold the cervix and provide a gentle outward pull with a tool called a tenaculum, which stabilizes the cervix and straightens out entrance of the uterus (which is typically curved at rest). This increases ease of insertion and helps with proper placement of the IUD. A suction cervical stabilizer can be used in place of the standard tenaculum, and they may reduce pain associated with the insertion procedure. The next step of insertion is measurement of the depth of the uterine cavity with a thin uterine sounding (measuring) device. The provider will then set the measured uterine depth on the IUD insertion device to ensure proper placement. The IUD insertion device will then be inserted through the cervix into the uterus to place the IUD. The procedure itself, if uncomplicated, should take no more than five to ten minutes. For immediate postpartum insertion, the IUD is inserted following delivery of the placenta. After vaginal deliveries, insertions can be done using placental forceps, a longer inserter specialized for postpartum insertions, or manually. After cesarean deliveries, the IUD is placed in the uterus with forceps or manually during surgery before suturing the uterine incision. Generally, the removal is uncomplicated and reported to be not as painful as the insertion because no instrument is inserted through the cervix.
Sources: en.wikipedia.org
==== In animals ==== PABA has been referred to historically as "vitamin Bx", but plays no direct role in animal cells and is hence no longer recognized as a vitamin. Animals (including humans) are unable to use PABA in any way and so require folate from dietary sources such as green leafy vegetables. PABA can play a role in the supply of folate to an animal via its microbiome; this is best demonstrated in the worm C. elegans, in which addition of PABA could increase folate production by resident E. coli and correct for deficiencies. The C. elegans folate transporter only works with the reduced form (tetrahydrofolate, THF and derivatives such as folinic acid), not regular folic acid. Any folic acid from the environment is only usable following spontaneous breakdown to PABA-glu, which E. coli uses to make THF. In contrast, humans can directly use oxidized folates thanks to the proton-coupled folate transporter and have no need for this detour; this "recycling" of PABA-glu would, at best, compensate for folate degradation. The above do not seem to apply in normal mammals, however. Despite detection of gut-produced folate being incorporated into mammals, ex vivo folate synthesis capacity of fecal bacteria have no correlation with the folate status of their donors. Furthermore, comparison with germ-free animals show that under a chow diet, the mouse microbiome is a net consumer of folate. The caveat is that the mouse chow is more folate-rich than typical human diets and may be encouraging a shift towards a folate-consuming microbiome.
The three substrates of this enzyme are D-glyceraldehyde 3-phosphate, phosphate (Pi), and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 1,3-bisphosphoglyceric acid, reduced NADH, and a proton. The enzyme can use nicotinamide adenine dinucleotide phosphate as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of a donor with NAD+ or NADP+ as an acceptor. The systematic name of this enzyme class is D-glyceraldehyde 3-phosphate:NAD(P)+ oxidoreductase (phosphorylating). Other names in common use include triosephosphate dehydrogenase (NAD(P)) (phosphorylating), and glyceraldehyde-3-phosphate dehydrogenase (NAD(P)) (phosphorylating).
During the Migration Period, the Jutland peninsula was home to several tribes. The Jutes inhabited the most northern part of the peninsula from Grenen to Olger's Dyke. This dyke, dating back to around the first century, served as the boundary between the Jutes in the north and the Angles in the south. This dyke lost its relevance in the 200s when the Angles expanded northward, leading to the establishment of a new dyke called the Wendish Dyke. The southern border of the Angles was marked by the marshes surrounding the Eider, that combined with the dense old-growth forest to the south of the river, formed a natural barrier. South of the forest lay the region now known as Holstein, which was divided between the Germanic Saxons, who inhabited the western part, and the Slavic Wagri, who lived in the eastern part. In the 8th century, the Wagri became part of the Slavic tribal confederation known as the Obotrites (also known as the Wends by the Danes and Saxons). During the 4th and early 5th centuries, a significant migration saw the Jutes, Angles, and Saxons depart from their homelands to settle in the British Isles. This mass exodus left much of the Jutland Peninsula sparsely populated, allowing the Danes from southern Scandinavia and the islands of Zealand, Funen, and other smaller Danish isles to migrate into the peninsula. They gradually settled the region, integrating the remaining Jutes and Angles who had not left for Britain. By the mid-5th century, the Danes had established settlements from Grenen in the north to just north of the Eider River and its marshes.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.